Category

NASDAQ

NextDecade and Mitsubishi Heavy Industries America Execute Engineering Services Agreement for Carbon Capture at Rio Grande LNG Project in Texas NASDAQ

NextDecade and Mitsubishi Heavy Industries America Execute Engineering Services Agreement for Carbon Capture at Rio Grande LNG Project in Texas

NextDecade and Mitsubishi Heavy Industries America Execute Engineering Services Agreement for Carbon Capture at Rio Grande LNG Project in Texas Houston, TX, Apr 15, 2021 - (JCN Newswire) - NextDecade Corporation (NextDecade) (NASDAQ: NEXT) and Mitsubishi Heavy Industries America, Inc. (MHIA), part of Mitsubishi Heavy Industries (MHI) Group, have announced…
bubmag
April 15, 2021
Alnylam Presents Positive Late-Breaking Data From Ongoing Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension NASDAQ

Alnylam Presents Positive Late-Breaking Data From Ongoing Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for the treatment of hypertension. Results were presented during a late-breaking oral presentation at the 2021 Joint Meeting…
bubmag
April 11, 2021
Off to the Races: Kryptoin Re-files Bitcoin ETF Opting to List on Cboe Over Nasdaq NASDAQ

Off to the Races: Kryptoin Re-files Bitcoin ETF Opting to List on Cboe Over Nasdaq

On April 9, 2021, the Delaware-based company and sponsor of the “Kryptoin Bitcoin ETF Trust” filed an S1 amendment for a bitcoin exchange-traded fund (ETF) with the U.S. Securities and Exchange Commission (SEC). The asset manager re-filed its 2019 ETF application and instead of leveraging NYSE, the company plans to…
bubmag
April 11, 2021
Positive Findings From Phase 1b Trial Of GlycoMimetics’ GMI-1359 To Be Presented At AACR 2021 Meeting NASDAQ

Positive Findings From Phase 1b Trial Of GlycoMimetics’ GMI-1359 To Be Presented At AACR 2021 Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell mobilization in the initial two patients treated with the Company's dual antagonist of E-selectin and CXCR4. Dorothy Sipkins, MD, PhD, Associate Research…
bubmag
April 10, 2021
GlycoMimetics To Present At AACR 2021 Meeting On Positive Therapeutic Effects Of GMI-1757 In A Pancreatic Adenocarcinoma Model NASDAQ

GlycoMimetics To Present At AACR 2021 Meeting On Positive Therapeutic Effects Of GMI-1757 In A Pancreatic Adenocarcinoma Model

GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a... GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results…
bubmag
April 10, 2021
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia NASDAQ

BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia

Author of the article: BRUKINSA is now commercially available in Canada following approval in March.Canadian patients now have access to the myBeiGene® patient support program. MISSISSAUGA, Ontario — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official…
bubmag
April 8, 2021